Pre- and post-treatment evaluation of lung function with Xenon-gas enhanced Dual-Energy CT-imaging in patients undergoing radiotherapy
Key facts
- Where
- Jette, BelgiumSee the site
- Phase
- 2/3. fázis
Where in Belgium
- UZ BrusselJette, BelgiumToborzás még nem indult
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- UZ Brussel
- Trial code
- EU 2025-521559-22-00
- Record updated
- 2026. február 5.
- Original description
The primary objective of this trial is to acquire high-resolution anatomical and functional information on lung ventilation using a gas mixture of 30 Vol% Xe in 70 Vol% O2 as contrast agent in combination with DECT-imaging in lung and breast cancer patients scheduled to undergo radiotherapy. Ventilation maps will be generated to evaluate the effect of radiotherapy on the lung parenchyma in lung and breast cancer patients.Read full original descriptionShow less
The primary objective of this trial is to acquire high-resolution anatomical and functional information on lung ventilation using a gas mixture of 30 Vol% Xe in 70 Vol% O2 as contrast agent in combination with DECT-imaging in lung and breast cancer patients scheduled to undergo radiotherapy. Ventilation maps will be generated to evaluate the effect of radiotherapy on the lung parenchyma in lung and breast cancer patients.
Inclusion: Lung and breast cancer having a TNM classification I-IIIa; Between 50 and 80 years old; No prior cancer treatment; Breath hold for 3 seconds; Patients who are in stable condition or who are not hospitalized in an ICU; Patients who are not suffering from COPD GOLD IV; Patients who signed informed consent forms.
Exclusion: No lung or breast cancer having a TNM classification I-IIIa; Received prior cancer treatment; Patients who are in an unstable condition or who are hospitalized in ICU; Younger than 50 or older than 80 years old; Cannot perform a 3 s breath hold; Patients who are suffering from COPD GOLD IV; Patients who did not sign informed consent forms.